NASDAQ:UMRX Cogent Biosciences (UMRX) Stock Price, News & Analysis → The ONE AI Stock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Free UMRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$8.85▼$9.2950-Day Range$2.35▼$13.0152-Week Range$0.29▼$3.72Volume1.24 million shsAverage Volume1.22 million shsMarket Capitalization$383.92 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsHeadlinesTrendsStock AnalysisCompetitorsHeadlinesTrends Get Cogent Biosciences alerts: Email Address Ad Porter & CompanyThe Single Biggest Breakthrough of the Decade Billionaires, Jeff Bezos, Bill Gates, Warren Buffett, and Sir Richard Branson are rallying behind this technology as well. In my new investigation, I detail why this technology is the single biggest breakthrough of the decade.Click here to watch it now. About Cogent Biosciences Stock (NASDAQ:UMRX)Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.Read More Ad Porter & CompanyThe Single Biggest Breakthrough of the Decade Billionaires, Jeff Bezos, Bill Gates, Warren Buffett, and Sir Richard Branson are rallying behind this technology as well. In my new investigation, I detail why this technology is the single biggest breakthrough of the decade.Click here to watch it now. UMRX Stock News HeadlinesMay 24, 2024 | msn.comCogent Bio spikes after updating late-stage data for lead assetMay 24, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Ardelyx (ARDX), Cogent Biosciences (COGT) and Immunocore Holdings (IMCR)May 13, 2024 | markets.businessinsider.comBuy Rating on Cogent Biosciences: Financial Stability and Promising Clinical Trials Fuel Positive OutlookMay 10, 2024 | markets.businessinsider.comAnalyst Issues Buy Rating on Cogent Biosciences Amid Clinical and Financial MilestonesMay 7, 2024 | msn.comCogent Biosciences EPS of -$0.62 misses by $0.11May 7, 2024 | investorplace.comCOGT Stock Earnings: Cogent Biosciences Misses EPS for Q1 2024April 24, 2024 | money.usnews.comCogent Biosciences IncFebruary 26, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Cogent Biosciences (COGT) and Altimmune (ALT)February 26, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (COGT) and Moderna (MRNA)February 26, 2024 | markets.businessinsider.comCogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsFebruary 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cogent Biosciences Ahead of Key Data Presentation on Bezuclastinib with Strong Upside PotentialFebruary 14, 2024 | marketwatch.comCogent Biosciences Stock Soars After $225M Private PlacementFebruary 14, 2024 | msn.comCogent Biosciences announces oversubscribed $225M private placementFebruary 9, 2024 | markets.businessinsider.comBuy Rating on Cogent Biosciences Amid Market Overreaction and Promising Drug ProspectsFebruary 8, 2024 | msn.comCiti starts Cogent Biosciences at buy, cites GI tumor drug potentialDecember 15, 2023 | markets.businessinsider.comBuy Rating Reiterated for Cogent Biosciences as Bezuclastinib Shows Promise in SUMMIT TrialDecember 13, 2023 | markets.businessinsider.comMaintaining Buy on Cogent Biosciences Amid Anticipation of Differentiating Data for BezuclastinibDecember 11, 2023 | markets.businessinsider.comCogent Biosciences Shares Fall Despite Positive Clinical Trial Updates For Systemic Mastocytosis TreatmentDecember 11, 2023 | markets.businessinsider.comDow Surges 100 Points; Cogent Biosciences Shares PlungeDecember 11, 2023 | markets.businessinsider.comCogent Reports Positive Data From Phase 2 APEX Trial Of Bezuclastinib In Systemic MastocytosisDecember 11, 2023 | msn.comCogent slumps after mid-stage data for rare disorder therapyNovember 21, 2023 | markets.businessinsider.comPotential Upside for Cogent Biosciences Due to Imminent Data Readout for Bezuclastinib and Underpriced SharesNovember 14, 2023 | markets.businessinsider.comPromising Clinical Trials and Strong Financial Position Justify Buy Rating for Cogent BiosciencesNovember 4, 2023 | markets.businessinsider.comPromising Clinical Trials and Strong Financial Position Support Buy Rating for Cogent BiosciencesOctober 28, 2023 | markets.businessinsider.comPromising Market Potential for Cogent Biosciences’ Bezuclastinib Spurs Buy RatingSee More Headlines Receive UMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/11/2020Today6/13/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:UMRX CUSIPN/A CIK1622229 Webwww.unumrx.com Phone(617) 945-5576FaxN/AEmployees72Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,830,000.00 Net Margins-96.84% Pretax MarginN/A Return on Equity-87.78% Return on Assets-52.14% Debt Debt-to-Equity Ratio0.18 Current Ratio2.90 Quick Ratio2.90 Sales & Book Value Annual Sales$22.50 million Price / Sales17.06 Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book8.69Miscellaneous Outstanding Shares42,469,000Free FloatN/AMarket Cap$383.92 million OptionableNot Optionable Beta3.93 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesAndrew R. RobbinsPresident, Chief Executive Officer & DirectorGeoffrey HodgeChief Technical Officer & Senior VP-OperationsJohn L. GreenChief Financial & Accounting OfficerJessica SachsChief Medical OfficerGreg MotzHead-ResearchKey CompetitorsAvadel PharmaceuticalsNASDAQ:AVDLBelite BioNASDAQ:BLTELigand PharmaceuticalsNASDAQ:LGNDSupernus PharmaceuticalsNASDAQ:SUPNArcus BiosciencesNYSE:RCUSView All Competitors UMRX Stock Analysis - Frequently Asked Questions How were Cogent Biosciences' earnings last quarter? Cogent Biosciences, Inc. (NASDAQ:UMRX) announced its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.03. The firm earned $0.53 million during the quarter. Cogent Biosciences had a negative net margin of 96.84% and a negative trailing twelve-month return on equity of 87.78%. What other stocks do shareholders of Cogent Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cogent Biosciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), KushCo (KSHB), Novan (NOVN), Aeterna Zentaris (AEZS) and Zosano Pharma (ZSAN). When did Cogent Biosciences IPO? Cogent Biosciences (UMRX) raised $75 million in an initial public offering (IPO) on Thursday, March 29th 2018. The company issued 5,800,000 shares at $12.00-$14.00 per share. Morgan Stanley and Cowen served as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers. This page (NASDAQ:UMRX) was last updated on 6/13/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages...Weiss Ratings | SponsoredLike Investing in Big Tech in the Early 2000s?More than a decade after the first Bitcoin was mined, people are finally realizing something very important......Manward Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe biggest lie in America unravels…Americans have been fed an insidious lie for decades. Fortunately, it's starting to unravel – and a few powerf...Stansberry Research | SponsoredGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...Market JAR | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.